The principle behind this approach is to leverage the high expression of CD56 in MCC for targeted delivery of the cytotoxic agent, thereby potentially enhancing the efficacy of the treatment while minimizing side effects [104]. Here, NCAM1 is linked to Merkel cell skin cancer.